Abstract | CONTEXT: Gonadotroph tumors represent approximatively one-third of anterior pituitary tumors, but despite their frequency, no medical treatment is currently recommended for them. This would be greatly needed because following surgery, which is the first-line treatment, a significant percentage of gonadotroph tumors regrow. EVIDENCE ACQUISITION: EVIDENCE SYNTHESIS: CONCLUSIONS: Gonadotroph tumors need better phenotyping in terms of both tumor cells and associated tumor microenvironment to improve their treatment. Until formal recommendations will be available, we provide the readers with our suggested approach for the management of gonadotroph tumors, management that should be discussed within multidisciplinary teams.
|
Authors | Mirela Diana Ilie, Gérald Raverot |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 105
Issue 10
(10 01 2020)
ISSN: 1945-7197 [Electronic] United States |
PMID | 32735647
(Publication Type: Journal Article, Review)
|
Copyright | © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: [email protected]. |
Chemical References |
- Antineoplastic Agents
- Dopamine Agonists
- Immune Checkpoint Inhibitors
- Radiopharmaceuticals
- Somatostatin
- Cabergoline
- Temozolomide
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Cabergoline
(therapeutic use)
- Clinical Trials as Topic
- Dopamine Agonists
(therapeutic use)
- Gonadotrophs
(pathology)
- Humans
- Immune Checkpoint Inhibitors
(therapeutic use)
- Pituitary Neoplasms
(pathology, therapy)
- Radiopharmaceuticals
(administration & dosage)
- Somatostatin
(administration & dosage, analogs & derivatives)
- Temozolomide
(therapeutic use)
- Treatment Outcome
|